Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Patients with type 2 diabetes usually do not die from diabetes, but from cardiovascular disease and strokes.
Read More »Real-World Benefits for SGLT-2 Inhibitors
New Information on SGLT-2 Inhibitors
Research presented at the American Heart Association provided new insight into two large diabetes drug trials, CANVAS and EMPA-REG OUTCOME.
Read More »Samuel Engel Part 1, Merck Vertis Met Studies
In part 1 of this Exclusive Interview, Dr. Samuel Engel talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about the results of the new SGLT-2, ertugliflozin.
Read More »More Acute Renal Failure Adverse Events With SGLT-2
SGLT-2 inhibitors were associated with more acute renal failure reports than other diabetes medications.
Read More »Dapagliflozin Added To Insulin For People with Type 1
Trial shows HbA1c reduced, hypoglycemia and DKA similar across study participants.
Read More »Two New Treatments Offer Type 1 Patients Greater Weight Loss and A1c Reduction
Trial results promising, but DKA still a concern with use of new once-daily pills.
Read More »Ertugliflozin, An SGLT-2, Meets Goals in Two Phase 3 Trials
The investigational sodium/glucose cotransporter 2 (SGLT2) inhibitor ertugliflozin (Merck), being developed to improve glycemic control in adults with type 2 diabetes, met the primary outcomes in two yearlong phase 3 trials, VERTIS SU and VERTIS SITA2.
Read More »SGLT-2 Inhibitors Safer and More Effective Than DPP-4s For Heart
New study finds lower occurrence of heart failure in older people with type 2.
Read More »EASD: SGLT-2/GLP-1 Combo Better Than Monotherapy
Trial finds improvement in control and weight loss.
Read More »Effects of SGLT-2 Inhibitors On UTIs and Genital Infections
Lowering HbA1c worth the risk of urinary tract and genital infections?
Read More »